Trials combining GILT [128] or MIDO [129] with HMA have not yielded encouraging results to date, though early data suggest that AZA/sorafenib (SORA) may be effective in patients with R/R AML and FLT3-ITD [130]. The gene discussed is FLT3; the disease is acute myeloid leukemia.